172 related articles for article (PubMed ID: 26928381)
1. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.
Rosenberg AS; Klein AK; Ruthazer R; Evens AM
Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381
[TBL] [Abstract][Full Text] [Related]
2. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.
Rosenberg AS; Ruthazer R; Paulus JK; Kent DM; Evens AM; Klein AK
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):684-692.e3. PubMed ID: 27771291
[TBL] [Abstract][Full Text] [Related]
3. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
Kampers J; Orjuela-Grimm M; Schober T; Schulz TF; Stiefel M; Klein C; Körholz D; Mauz-Körholz C; Kreipe H; Beier R; Maecker-Kolhoff B
Leuk Lymphoma; 2017 Mar; 58(3):633-638. PubMed ID: 27685149
[TBL] [Abstract][Full Text] [Related]
4. Small intestinal involvement by lymphoproliferative disorders post-renal transplantation: a report from the post-transplant lymphoproliferative disorder international survey.
Khedmat H; Taheri S
Saudi J Kidney Dis Transpl; 2013 May; 24(3):487-94. PubMed ID: 23640619
[TBL] [Abstract][Full Text] [Related]
5. Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Twist CJ; Hiniker SM; Gratzinger D; Gutkin PM; Merriott DJ; Iagaru A; Link MP; Donaldson SS
Pediatr Blood Cancer; 2019 Aug; 66(8):e27803. PubMed ID: 31062898
[TBL] [Abstract][Full Text] [Related]
6. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J
Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093
[TBL] [Abstract][Full Text] [Related]
8. Survival of Patients With Second Primary Hodgkin Lymphoma.
Budnik J; Doucette C; Milano MT; Constine LS
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):316-323.e2. PubMed ID: 32014390
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
10. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
[TBL] [Abstract][Full Text] [Related]
11. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
[TBL] [Abstract][Full Text] [Related]
13. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.
Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B
J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
[TBL] [Abstract][Full Text] [Related]
16. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation.
Yoon JH; Lee S; Kim HJ; Lee JW; Min WS; Chung BH; Yang CW; Kim YS; Kim JI; Moon IS; Oh EJ; Park GS; Cho SG
Transpl Int; 2014 Jul; 27(7):721-32. PubMed ID: 24684689
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.
Francis A; Johnson DW; Craig J; Teixeira-Pinto A; Wong G
Kidney Int; 2018 Oct; 94(4):809-817. PubMed ID: 30173897
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
[TBL] [Abstract][Full Text] [Related]
20. Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK
Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
